Fulgent is a technology-driven diagnostics and therapeutics company operating two core businesses: laboratory services and therapeutic development. The laboratory services division provides clinical and research testing through anatomic pathology, precision diagnostics using next-generation sequencing, biopharma contract testing, and a telemedicine platform, serving institutional customers, insurance payors, and direct-pay patients while leveraging proprietary algorithms, AI technology, and laboratory information systems. The therapeutic development business, acquired through Fulgent Pharma, focuses on developing cancer treatments using a nanoencapsulation platform designed to improve drug efficacy and safety profiles, with a clinical pipeline including Phase 1/1b and Phase 2 candidates in solid tumors.